Faricimab▼ in Neovascular Age-Related Macular Degeneration: 48-Week Results by Dosing Cohort in the Phase 3 TENAYA/LUCERNE Trials
This presentation reports the pooled week 48 primary results by treatment cohort from the phase 3 TENAYA and LUCERNE trials of faricimab▼ , a bispecific antibody that independently binds and neutralizes Ang-2 and VEGF-A, in patients with neovascular age-related macular degeneration. TENAYA and LUCERNE investigated the efficacy, safety, and durability of faricimab▼ , administered at individualized treatment intervals of up to every 16 weeks compared with aflibercept administered every 8 weeks.